Treating patients with a drug called aprotinin reduces the risk of stroke by 47 percent in patients undergoing coronary artery bypass graft (CABG) surgery, according to a study published in the Journal of Thoracic and Cardiovascular Surgery. The study, a large-scale analysis evaluating data from 35 CABG studies, determined that use of aprotinin reduced the need for a blood transfusion by 39 percent. Blood transfusions during CABG surgery have been associated with an increased risk of stroke. Stroke and neurological injury occurs in five percent of the more than 300,000 CABG surgeries performed annually.